NASDAQ:MGTX - MeiraGTx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.00
  • Forecasted Upside: 244.43 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.71
▲ +0.62 (7.66%)

This chart shows the closing price for MGTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MeiraGTx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGTX

Analyst Price Target is $30.00
▲ +244.43% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MeiraGTx in the last 3 months. The average price target is $30.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 244.43% upside from the last price of $8.71.

This chart shows the closing price for MGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in MeiraGTx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Chardan CapitalReiterated RatingBuy$46.00Medium
5/13/2022BarclaysLower Price Target$32.00 ➝ $18.00High
5/12/2022Piper SandlerLower Price Target$40.00 ➝ $30.00High
10/21/2021Bank of AmericaReiterated RatingBuy$26.00Low
7/1/2021Chardan CapitalReiterated RatingBuyLow
5/13/2021Evercore ISIInitiated CoverageBuy$27.00High
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$27.00High
9/15/2020Bank of AmericaInitiated CoverageBuy$20.00High
8/16/2020Chardan CapitalReiterated RatingBuy$45.00Medium
7/17/2020Piper SandlerReiterated RatingBuy$40.00High
7/17/2020Chardan CapitalReiterated RatingBuy$45.00High
5/31/2020Chardan CapitalReiterated RatingBuy$45.00High
5/9/2020Chardan CapitalReiterated RatingBuy$45.00High
3/22/2020Chardan CapitalReiterated RatingBuy$45.00Low
3/2/2020Chardan CapitalReiterated RatingBuy$45.00Medium
1/30/2020Chardan CapitalReiterated RatingBuy$45.00Medium
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$40.00Low
12/16/2019Chardan CapitalReiterated RatingBuy$45.00Low
9/23/2019Chardan CapitalReiterated RatingBuy$45.00Low
9/3/2019Piper Jaffray CompaniesInitiated CoverageOverweight$40.00High
5/15/2019BarclaysBoost Price TargetPositive$20.00 ➝ $30.00High
5/14/2019Chardan CapitalReiterated RatingBuyHigh
2/27/2019Chardan CapitalBoost Price TargetBuy ➝ Buy$30.00 ➝ $40.00High
1/31/2019Chardan CapitalReiterated RatingBuy$30.00High
10/16/2018Chardan CapitalReiterated RatingBuy$30.00High
8/23/2018Chardan CapitalInitiated CoverageBuyHigh
7/9/2018Evercore ISIInitiated CoverageOutperform$21.00High
7/3/2018Bank of AmericaInitiated CoverageBuyHigh
7/3/2018BarclaysInitiated CoverageOverweight$20.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

-0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/24/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/22/2022
  • 0 very positive mentions
  • 13 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
5/22/2022

Current Sentiment

  • 0 very positive mentions
  • 13 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
MeiraGTx logo
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Read More

Today's Range

Now: $8.71
Low: $8.27
High: $8.83

50 Day Range

MA: $12.01
Low: $8.09
High: $14.38

52 Week Range

Now: $8.71
Low: $7.73
High: $24.89

Volume

240,432 shs

Average Volume

145,963 shs

Market Capitalization

$389.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of MeiraGTx?

The following sell-side analysts have issued reports on MeiraGTx in the last year: Bank of America Co., Barclays PLC, Chardan Capital, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for MGTX.

What is the current price target for MeiraGTx?

0 Wall Street analysts have set twelve-month price targets for MeiraGTx in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 244.4%.
View the latest price targets for MGTX.

What is the current consensus analyst rating for MeiraGTx?

MeiraGTx currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGTX will outperform the market and that investors should add to their positions of MeiraGTx.
View the latest ratings for MGTX.

How do I contact MeiraGTx's investor relations team?

MeiraGTx's physical mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company's listed phone number is (646) 860-7985 and its investor relations email address is [email protected] The official website for MeiraGTx is www.meiragtx.com. Learn More about contacing MeiraGTx investor relations.